Sun Pharma Recalled Lidocaine Ointment and Nystatin Cream
Healthcare providers should verify stock after voluntary recalls for stability and assay failures.
Updated on Sept. 26, 2026 in Healthcare
Live Poll
Do you trust that pharmaceutical companies maintain adequate quality control over prescription medications?
On August 31, 2026, Sun Pharmaceutical Industries initiated a voluntary recall of Nystatin cream and 65,328 jars of Lidocaine ointment in the U.S. market. The products were pulled after failing to meet quality specifications during stability and assay testing.
Why it matters
The recall highlights the critical importance of supply chain quality control in maintaining regulatory compliance and patient safety. These failures demonstrate the risks inherent in long-term product stability, necessitating rigorous inventory monitoring for operators.
Sun Pharmaceutical Industries initiated the voluntary recall of 65,328 jars of lidocaine ointment following failures during 24-month stability testing.
The players
Sun Pharmaceutical Industries
A multinational pharmaceutical company that manufactures and markets a broad range of generic and specialty drug products.
FDA
The federal agency responsible for regulating pharmaceutical quality, safety, and supply chain compliance in the United States.
The details
The recalls were triggered when the products failed to meet mandatory assay and stability specifications during routine testing. The lidocaine ointment was manufactured at a facility in Brampton, Canada, while the Nystatin cream was produced in Haifa Bay, Israel. The FDA has classified the lidocaine recall as a Class II action, which denotes that the affected items could cause temporary or medically reversible adverse health consequences if used.
Timeline
August 31, 2026: Sun Pharmaceutical Industries initiated the voluntary recall of Lidocaine ointment.
Market Landscape
This action follows the standard enforcement protocols set by the FDA Class II recall classification system. The recall highlights ongoing industry-wide challenges in maintaining product integrity throughout multi-year stability cycles.
Operators must immediately audit current inventory against the recalled batch numbers to prevent the distribution of non-compliant medication. Consult with qualified counsel to document your response actions and ensure compliance with regulatory recall protocols.
The takeaway
Product stability testing is a primary failure point that operators should monitor through their supply chain management systems. Verify all batch numbers against FDA recall notifications to ensure that your facility remains compliant and patients remain safe.
Further reading
For more on industry regulatory standards and supply chain monitoring, visit the Healthcare section.
Source note: This article includes information reported by ETPharma.
Live Poll
Do you trust that pharmaceutical companies maintain adequate quality control over prescription medications?
